Rafael Holdings (RFL) FCF Margin (2017 - 2026)
Rafael Holdings' (RFL) quarterly FCF Margin came in at 4069.27% in Q2 2026, down 318833.0% year-over-year from N/an in Q2 2025, and down 14.13% quarter-over-quarter from 3565.4% in Q1 2026.
Analysis
Rafael Holdings (RFL) FCF Margin (2017 - 2026) Analysis & Trends
Rafael Holdings (RFL) has reported FCF Margin for 10 consecutive years, with 4069.27% the latest figure, recorded in Q2 2026.
- On a quarterly basis, FCF Margin fell 318833.0% year-over-year to 4069.27% in Q2 2026; TTM through Apr 2026 was 3264.18%, a 170121.0% decrease from a year earlier, with the FY2025 full-year figure at 2064.12%, up 6351.0% from the prior year.
- FCF Margin was 4069.27% for Q2 2026 at Rafael Holdings, down from 3565.4% in the prior quarter.
- Over five years, FCF Margin peaked at 880.94% in Q2 2025 and troughed at 13638.16% in Q2 2022.
- A 5-year average of 3997.44% and a median of 2985.53% in 2025 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin plunged 1332250 bps in 2022 and jumped 1178745 bps in 2023, its largest moves.
- Over 5 years, FCF Margin stood at 3685.71% in 2022, then grew by 15 bps to 3136.76% in 2023, then climbed by 24 bps to 2381.25% in 2024, then declined by 19 bps to 2835.83% in 2025, then slumped by 43 bps to 4069.27% in 2026.
- The last three FCF Margin figures came in at 4069.27% (Q2 2026), 3565.4% (Q1 2026), and 2835.83% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -18,629.40% |
| 10 | Rafael Holdings | 117.57 Mn | 117.57 Mn | 171,000.00 | -4,069.27% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -4,069.27% |
| Jan 31, 2026 | -3,565.40% |
| Oct 31, 2025 | -2,835.83% |
| Jul 31, 2025 | -2,964.57% |
| Apr 30, 2025 | -880.94% |
| Jan 31, 2025 | -3,006.49% |
| Oct 31, 2024 | -2,381.25% |
| Jul 31, 2024 | -1,750.91% |
| Apr 30, 2024 | -1,783.04% |
| Jan 31, 2024 | -3,719.12% |
| Oct 31, 2023 | -3,136.76% |
| Jul 31, 2023 | -2,129.41% |
| Apr 30, 2023 | -1,850.70% |
| Jan 31, 2023 | -7,920.00% |
| Oct 31, 2022 | -3,685.71% |
| Jul 31, 2022 | -2,757.97% |
| Apr 30, 2022 | -13,638.16% |
| Jan 31, 2022 | -9,878.38% |
| Oct 31, 2021 | -3,404.71% |
| Jul 31, 2021 | 315.91% |